Überexpression des Vaskulären Endothelialen Wachstumsfaktor Rezeptor 2 (VEGFR2) bei Langzeitüberlebenden eines fortgeschrittenen serösen Ovarialkarzinoms [thesis]

Jun Guan, Universitätsbibliothek Der FU Berlin
2020
Objective: The prognosis for high-grade serous ovarian cancer (HGSOC) patients is poor. There are no defined biomarkers to identify between good and poor prognosis at the present. This study is to analyze if there are differences in angiogenesis biomarkers between long-term survivors and poor survivors, using tumor samples from a large cohort of long-term survivors and matched controls. Methods: Tumor samples of 62 "long-term survivors" and 62 matched controls were identified from the Tumor
more » ... Ovarian Cancer. All patients were diagnosed as HGSOC in advanced stages [Federation International of Gynecology and Obstetrics (FIGO) stage III-IV]. Patients with no relapse for at least 5 years (5+ years) after primary platinum-based chemotherapy were defined as "long-term survivor", and patients who had the first relapse occurred between 6 months and 3 years were selected for controls. Long-term and control cohorts were matched by age and post-surgical tumor residuals. A pathological review has been performed in order to prove the high-grade serous histology. Immunohistochemistry was performed on tumor samples to determine the expressions of vascular endothelial growth factor (VEGF) A and VEGF receptor 2 (VEGFR2). Chi-square test or Fisher's test were used to access the difference in biomarkers between long-term and control groups. Results: VEGFA expression was found to be significantly correlated with VEGFR2 expression (p<0.0001, Spearman coefficient 0.347). Although VEGFA expression was not related to 5+ years progression-free survival (PFS) (p=0.075), VEGFR2 overexpression was seen more frequently in long-term survivors (77.4%, 48/62) than in controls (51.6%, 30/62, p=0.001). The difference in VEGFR2 remained significant after adjusting FIGO stage and VEGFA expression (p=0.005). Within the whole cohort of analyzed patients, the highest expression level of VEGFR2 was seen in subgroup of patients with PFS longer than 10 years (10+ years) (p=0.001). Conclusion: Our study showed a significant correlation between VEGFR [...]
doi:10.17169/refubium-27718 fatcat:upb45d55zbbjbbsl775iujwore